{
    "clinical_study": {
        "@rank": "8092", 
        "arm_group": [
            {
                "arm_group_label": "CHF6001", 
                "arm_group_type": "Experimental", 
                "description": "CHF6001 DPI (Dry Powder Inhaler) once daily"
            }, 
            {
                "arm_group_label": "Roflumilast", 
                "arm_group_type": "Active Comparator", 
                "description": "Roflumilast, tablet, once daily"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase IIa study in COPD patients aimed to evaluate the safety, tolerability\n      ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in\n      blood, and on pulmonary function) and on  pharmacokinetics of CHF 6001 (a PDE4 inhibitor)\n      after 28-days of daily inhaled dosing."
        }, 
        "brief_title": "Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent obtained prior to any study-related procedures.\n\n          2. Male or female aged between 40 and 70 years inclusive.\n\n          3. Current or past smoker of at least 10 pack/years\n\n          4. BMI in the range of 18-35 Kg/m2\n\n          5. GOLD Stage 2 and 3 COPD subjects\n\n          6. A history of chronic bronchitis defined as chronic cough and sputum production\n\n          7. At screening, subjects must be able to produce an adequate induced sputum sample\n\n          8. Female subjects: post-menopausal women having at least 12 months of natural\n             (spontaneous) amenorrhea, or women of childbearing potential using two acceptable\n             methods of contraception for the duration of the study and for the following three\n             months\n\n        Exclusion criteria:\n\n          1. Female subjects: pregnant or lactating women\n\n          2. Past or current history of asthma\n\n          3. History of clinically significant hypotensive episodes\n\n          4. History or symptoms of significant cardiovascular disease\n\n          5. History or symptoms of significant neurological disease\n\n          6. Unstable concurrent disease\n\n          7. An abnormal and clinically significant 12-lead ECG\n\n          8. Clinically relevant abnormal laboratory values\n\n          9. Use of oral or systemic corticosteroids oral and/or nebulised Beta2 agonists and/or\n             antibiotics within 6 weeks preceding the screening visit\n\n         10. Moderate or severe hepatic impairment (Child-Pugh B or C)\n\n         11. Intolerance/hypersensitivity or any contraindication to treatment with roflumilast,\n             tiotropium bromide or salbutamol or any of the excipients contained in the\n             formulations used in the study\n\n         12. Chronic use of any other medication for treatment of lung disease like xanthines,\n             antileukotrienes, systemic and inhaled corticosteroids, long acting beta2- agonists,\n             roflumilast (other than the study drug) and cromoglycates\n\n         13. Long term (at least 12 hours daily) use of oxygen therapy for chronic hypoxemia.\n\n         14. Having received an investigational medicinal drug within 30 days prior to study entry\n\n         15. Blood draws of 250 mL or more within 45 days prior to enrolment into the study.\n\n         16. Known respiratory disorders other than COPD.\n\n         17. History of alcohol dependency, or substance abuse\n\n         18. Inability to comply with the study Protocol for any other reason."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730404", 
            "org_study_id": "CCD-1201-PR-0079"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF6001", 
                "intervention_name": "CHF6001 DPI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Roflumilast", 
                "intervention_name": "Roflumilast", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "Ireland"
                    }, 
                    "name": "Celerion"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harrow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Parexel, early phases"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Medicines Evaluation Unit Ltd"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Freeman Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Nottingham University Hospitals NHS Trust"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Ireland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Double-dummy, Placebo and Active-controlled, Three-way Crossover Study to Evaluate the Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI (1200 \u00b5g Daily) in Subjects With COPD", 
        "overall_contact": {
            "email": "O.Esposito@chiesi.com", 
            "last_name": "Oriana Esposito, PhD", 
            "phone": "+39 0521 1689204"
        }, 
        "overall_official": [
            {
                "affiliation": "MEU", 
                "last_name": "Dave Singh, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Freeman Hospital", 
                "last_name": "Anthony DeSoyza, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Celerion", 
                "last_name": "Stephen Smith, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Nottingham University Hospitals NHS Trust", 
                "last_name": "Tim Harrison, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Parexel, early phases", 
                "last_name": "Muna Albayaty, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The number and percentage of subjects experiencing AEs, ADRs, serious AEs and AEs leading to study withdrawal.", 
                "measure": "Adverse events, adverse drug reactions, serious adverse.", 
                "safety_issue": "Yes", 
                "time_frame": "After 28 days of treatment"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "After 28 days of treatment"
            }, 
            {
                "measure": "12-lead ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "After 28 days of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics of CHF 6001 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "After 28 days of treatment"
            }, 
            {
                "description": "Biomarkers of inflammation", 
                "measure": "Induction of sputum", 
                "safety_issue": "No", 
                "time_frame": "After 28 days of treatment"
            }, 
            {
                "measure": "Baseline Dyspnea Index and Transition Dyspnea Index Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "After 28 days of treatment"
            }, 
            {
                "measure": "Lung function measurements", 
                "safety_issue": "Yes", 
                "time_frame": "After 28 days of treatment"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}